Home › Funds › Sanofi › GRTX

Sanofi position in GRTX

Electra Therapeutics Inc

Sanofi reported holding 2,461,948 shares of GRTX (Electra Therapeutics Inc) in its Q3 2026 13F filing — a position valued at US$27.7M, representing 4.40% of its reported portfolio and ranking #9 among its reported holdings. Sanofi first reported this position in Q3 2026.

Latest position (Q3 2026)2.46M sh
Reported value held$27.70M
Portfolio Weight4.40%
First reportedQ3 2026
Last changeNew
Updated2026-11-05

Last updated: 2026-11-05 · Source: SEC EDGAR Form 13F-HR

How Sanofi's GRTX position evolved

Sanofi first disclosed a stake in GRTX in Q3 2026 at 2,461,948 shares (US$27.7M).

Quarter by quarter

QuarterSharesValueChange
Q3 2026 2.46M $27.70M New

About GRTX and 13F data

GRTX (Electra Therapeutics Inc) is a company whose sector is not yet classified in our data. 1 other funds we track also report a position in GRTX. Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GRTX

No other tracked fund reports a position in GRTX.

All GRTX fund holders →

FAQ

How long has Sanofi held GRTX?

Sanofi has disclosed GRTX holdings in 1 of the last 1 reported quarters, going back to Q3 2026.

What is Sanofi's current position in GRTX?

As of Q3 2026, Sanofi holds 2.46M shares of GRTX (Electra Therapeutics Inc), valued at $27.70M, representing 4.40% of its reported portfolio and ranking #9.

Has Sanofi been buying or selling GRTX?

In the latest 13F filing (Q3 2026), Sanofi newly opened its position in GRTX.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.